Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00297817 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents
A Phase 2 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT00297817 is a Phase 2 study that has completed, run by Novartis Vaccines. The registered enrollment target is 203 participants.
The verdict
NCT00297817, a Phase 2 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.
Interventions
- BIOLOGICAL serogroup B meningococcal vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00297817
The ClinicalTrials.gov registry entry for NCT00297817 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which serogroup B meningococcal vaccine is the first listed.
NCT00297817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00297817 about?
NCT00297817 is a clinical study titled "Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents". The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.
What is the current status of trial NCT00297817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2006-02. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00297817?
The interventions under investigation include: serogroup B meningococcal vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00297817?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.